Rational Design of Antirheumatic Prodrugs Specific for Sites of Inflammation

OBJECTIVE: Biologic drugs, such as the anti–tumor necrosis factor (anti‐TNF) antibody adalimumab, have represented a breakthrough in the treatment of rheumatoid arthritis. Yet, concerns remain over their lack of efficacy in a sizable proportion of patients and their potential for systemic side effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Onuoha, Shimobi C., Ferrari, Mathieu, Sblattero, Daniele, Pitzalis, Costantino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832285/
https://www.ncbi.nlm.nih.gov/pubmed/26097196
http://dx.doi.org/10.1002/art.39232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832285/
https://www.ncbi.nlm.nih.gov/pubmed/26097196
http://dx.doi.org/10.1002/art.39232

Ejemplares similares